No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human SLC1A5 Antibodies:
anti-Mouse (Murine) SLC1A5 Antibodies:
anti-Rat (Rattus) SLC1A5 Antibodies:
Go to our pre-filtered search.
Cow (Bovine) Polyclonal SLC1A5 Primary Antibody for IHC, WB - ABIN2775316
Bungard, McGivan: Identification of the promoter elements involved in the stimulation of ASCT2 expression by glutamine availability in HepG2 cells and the probable involvement of FXR/RXR dimers. in Archives of biochemistry and biophysics 2005
Show all 4 Pubmed References
Human Polyclonal SLC1A5 Primary Antibody for IF (p), IHC (p) - ABIN669081
Huang, Zhao, Zhao, Wu, Jiang, Ma, Zhang: Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer. in International journal of clinical and experimental pathology 2014
Human Polyclonal SLC1A5 Primary Antibody for ICC, IF - ABIN4354074
Sun, Yu, Wu, Chen, Shi, Zheng, Xu: GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma. in PLoS ONE 2016
Relative to structures of other SLC1 members, ASCT2 is in the most extreme inward-oriented state, with the transport domain largely detached from the central scaffold domain on the cytoplasmic side
ASCT2 regulates gastric cancer proliferation via reactive oxygen species induced mitochondrial pathway.
The ASCT2 deficiency was compensated by increased levels of sodium neutral amino acid transporter 1 (SNAT1 or SLC38A1) and SNAT2 (SLC38A2) in ASCT2ko 143B cells, mediated by a GCN2 EIF2alpha kinase (GCN2)-dependent pathway, but this compensation was not observed in ASCT2ko HCC1806 cells.
Herein we report the preclinical development of V-9302, a competitive small molecule antagonist of transmembrane glutamine flux that selectively and potently targets the amino acid transporter ASCT2.
data reveal a role for SNX27 in glutamine uptake and amino acid-stimulated mTORC1 activation via modulation of ASCT2 intracellular trafficking
Data suggest that amino acid uptake via ASCT2/SLC1A5 is required for cell proliferation/tumor growth independently of LAT1/SLC7A5; in part, these studies were conducted in lung and colon adenocarcinoma cell lines and involved gene knockout techniques. (ASCT2/SLC1A5 = solute carrier family-1 member-5; LAT1/SLC7A5 = solute carrier family-7 member-5)
This study provides the metabolic molecule SLC1A5 as a potential therapeutic target to increase the efficacy of cetuximab on colorectal cancer
Results demonstrated that ASCT2 and pmTOR protein levels were significantly higher in epithelial ovarian cancer (EOC) tissues and predicting a poor prognosis. The expression levels of ASCT2 and pmTOR in EOC were positively correlated indicating a synergistic effect on the growth and development of early EOC.
intronic variants of the ASCT2 gene have roles in hampering the splicing process and in longevity
These data collectively establish that in an in vitro context, human epithelial and mesenchymal hepatocellular carcinoma cell lines adapt to ASCT2 or LAT1 knockout.
SLC1A5 expression is increased in tumor samples from esophageal cancer patients, and downregulation of SLC1A5 inhibited cell cycle progression and esophageal cancer growth.
Our results indicate that overexpression of SLC1a5 is associated with shorter overall survival in non-small cell lung cancer
the experimental data allowed identifying C467 residue as crucial for substrate binding and for transport activity modulation of hASCT2.
Results suggest that ASCT1/2 may play an important role in regulating extracellular d-serine and NMDA receptor-mediated physiological effects and that ASCT1/2 inhibitors have the potential for therapeutic benefit.
Our data confirm the heterogeneity of breast tumors at a functional proteomic level and dissects the relationship between metabolism-related proteins, pathological features and patient survival. These observations highlight the importance of SHMT2 and ASCT2 as valuable individual prognostic markers and potential targets for personalized breast cancer therapy
ASCT2 was significantly overexpressed in the gastric cancer (GC) samples compared with adjacent non-cancerous gastric mucosa, in contrast, a significantly higher level of glutamine synthetase (GS) expression was observed in normal tissues than in GC samples compared with adjacent non-cancerous gastric mucosa.
These results indicated that ASCT2 (SLC1A5) could be a novel therapeutic target against KRAS-mutant colorectal cancer.
AR signaling promoted glutamine metabolism by increasing the expression of the glutamine transporters SLC1A4 and SLC1A5, genes commonly overexpressed in prostate cancer. Correspondingly, gene expression signatures of AR activity correlated with SLC1A4 and SLC1A5 mRNA levels in clinical cohorts.
Results provide evidence that ASCT2 enhances glutamine uptake in glycolipid-enriched microdomain/rafts in GD2(+) small-cell lung cancer cells, leading to the enhancement of cell proliferation and migration.
High ASCT2 expression is associated with head and neck squamous cell carcinoma.
The ability of L-4FPG to penetrate the brain makes this compound a useful tool to further evaluate the function of ASCT1 and ASCT2 transporters in the CNS.
Data show that SERT associates with ASCT2 (alanine-serine-cysteine-threonine 2), a member of the solute carrier 1 family co-expressed with SERT in serotonergic neurons and involved in the transport of small neutral amino acids across the plasma membrane.
These findings highlight a mechanism of T cell activation involving ASCT2-dependent integration of the T cell receptor signal and a metabolic signaling pathway.
used as receptor by HERV-W Env glycoproteins when their sites for N-linked glycosylation are eliminated by mutagenesis
results strongly suggest that combinations of amino acid sequence changes and N-linked oligosaccharides in a critical carboxyl-terminal region of extracellular loop 2 (ECL2) control retroviral utilization of both the ASCT1 and ASCT2 receptors
amino acid transporter B(0)/ASC transporter 2 expression is necessary for SK-Hep cell growth
ASCT1 and ASCT2 mRNA were expressed in cultured blood-brain barrier[BBB] cells; expression of ASCT2 mRNA was 6.7-fold greater. ASCT2 is localized at the abluminal side of the mouse BBB, suggesting a key role in l-isomer-selective Asp transport at the BBB
data support ASCT2 function in both neuron and astrocyte cultures and identify a discrepancy between observed asc-1 immunoreactivity and lack of functional asc-1 activity in neuron cultures, elucidating processes that govern D-serine regulation
The SLC1A5 gene encodes a sodium-dependent neutral amino acid transporter that can act as a receptor for RD114/type D retrovirus (Larriba et al., 2001
neutral amino acid transporter B(0)
, RD114 virus receptor
, RD114/simian type D retrovirus receptor
, baboon M7 virus receptor
, neutral amino acid transporter B
, sodium-dependent neutral amino acid transporter type 2
, solute carrier family 1 member 5
, alanine/serine/cysteine/threonine transporter 2
, neutral amino acid transporter B0
, ASC-like Na(+)-dependent neutral amino acid transporter ASCT2
, insulin-activated amino acid transporter
, solute carrier family 1, member 7
, CAZ-associated structural protein
, H4-system ASC-like transporter
, sodium-dependent neutral amino acid transporter ASCT2